Syneron Medical Ltd (ELOS) Tops Q1 EPS by 1c

Syneron Medical Ltd (NASDAQ: ELOS) reported Q1 EPS of $0.02, $0.01 better than the analyst estimate of $0.01. Revenue for the quarter came in at $63.4 million versus the consensus estimate of $62.08 million.

As of March 31, 2015, the Company's overall cash position including cash, short-term bank deposits and marketable securities amounted to $99.8 million, compared to $110.4 million as of December 31, 2014. Cash use in the first quarter 2015 included investments in inventory to support anticipated growth in 2015 and to account for the Company's strong fourth quarter results, as well as other non-recurring payments, along with investment in a new ERP system. The reduction in cash position also included the repurchase of 328,358 shares of Syneron stock during the first quarter 2015 at an average price of $11.93 for $3.9 million under the Company's previously authorized $20 million share repurchase program. Since December 2014, the Company has repurchased a total of 376,642 shares at an average price of $11.69 for $4.4 million under this program.

For earnings history and earnings-related data on Syneron Medical Ltd (ELOS) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79